In 2023, the American Society of Anesthesiologists (ASA) issued guidelines advising patients to discontinue GLP-1 receptor agonists (GLP1-RAs) a week before surgery, citing concerns over potential operative complications, leading to delayed or rescheduled surgeries across the U.S. Dr. David Klonoff, a diabetes researcher and Endocrinologist at Mill Peninsula Medical Center, thought it was curious that…
Beyond diabetes and obesity: Can GLP-1 therapies also transform chronic disease treatment?
Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide have cemented their status as two of the most successful drugs in recent memory. Recent projections have estimated that the drug class could fetch $44 billion by 2030 and $71 billion by 2032. But GLP-1 sales could potentially reach greater heights as these therapies move beyond…
Beyond GLP-1: OrsoBio targets mitochondria to treat metabolic disorders from a new and potentially complementary angle
Emerging from stealth in late 2022, Palo Alto–based biopharma startup OrsoBio announced four development programs targeting severe metabolic disorders. The CEO and founder, Dr. Mani Subramanian and chief medical officer and head of development Dr. Rob Myers formerly worked at Gilead. Founded in 2020 with a quest to “try to modulate energy metabolism in severe…